Virtual Library
Start Your Search
F. Tronc
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-043 - Assessing Treatment Strategies for Lung Cancer in Octogenarians: Insights From a Cohort of 337 Patients (ID 1216)
09:30 - 09:30 | Author(s): F. Tronc
- Abstract
Background:
Aging increases the incidence of lung cancer in octogenarians. In this population, only limited data about treatment strategies and results are available, as those patients are usually not eligible for clinical trials; meanwhile, previously reported cohorts mostly focused on early-stage tumors. Our objective was then to provide a global picture of the treatment strategies for lung cancer in octogenerians, and to parallel those with available standards.
Methods:
Retrospective observational study of all consecutive patients aged 80 or more, with pathologically-confirmed lung cancer, and diagnosed at the Hospices Civils de Lyon between January 2005 and April 2014.
Results:
337 patients were included, 298 (88%) with non-small cell lung cancer (NSCLC), and 39 (12%) with small-cell lung cancer. For NSCLC, tumor was stage I, II, III, and IV in 10%, 9%, 25% et 57% of cases, respectively. Overall survival was 8.4 months. Geriatric assessment had been done only for 11% of patients. Overall, a standard treatment strategy - i.e. based on available recommendations and guidelines - was conducted for 42% of patients, while 24% received non-standard treatment, and 34% best supportive care only. At multivariate analysis, favorable prognostic factors on overall survival were performance status 0-1 (p<0.001), stage I/II (p<0.001), adenocarcinoma histology (p=0.026), and a standard treatment strategy (p<0.001). In the setting of metastatic NSCLC, 35% of patients received chemotherapy, the most frequent regimen being carboplatine and paclitaxel.
Conclusion:
Octogenarians with lung cancer are eligible for antitumor treatment in nearly 70% of cases, consisting of standard, recommended therapy in about half of the cases. Our data provide a unique overview of the management of octogenarians with lung cancer, to foster future prospective studies dedicated to this subset of patients.
